The Pulse Check

Feb 20, 2026

•

10 min read

The Three-Day Market Update

Jason Segal

The Pulse Check

The Price of Buying Time: The Adherium (ASX: ADR) Story

Feb 17, 2026

•

12 min read

The Price of Buying Time: The Adherium (ASX: ADR) Story

Jason Segal

Clarity Pharmaceuticals (ASX: CU6)

Feb 16, 2026

•

13 min read

The Path to Blue-Chip: The Clarity Pharmaceuticals (ASX: CU6) Story

Jason Segal

The Pulse Check

Feb 13, 2026

•

10 min read

Why do stocks fall on good news

Jason Segal

The Pulse Check

The Greatest Wealth Creator in Australian Biotech: The CSL Story

Feb 12, 2026

•

11 min read

The Greatest Wealth Creator in Australian Biotech: The CSL Story

Jason Segal

The Pulse Check

Why I'm not catching the CSL falling knife

Feb 11, 2026

•

8 min read

Why I'm not catching the CSL falling knife

Jason Segal

The Pulse Check

A 20-Year Overnight Success: The Memphasys (ASX: MEM) Story.

Feb 10, 2026

•

12 min read

A 20-Year Overnight Success: The Memphasys (ASX: MEM) Story.

Jason Segal

The Pulse Check

Why fundamental analysis doesn't work for Biotech Stocks

Feb 9, 2026

•

8 min read

Why fundamental analysis doesn't work for Biotech Stocks

Jason Segal

The Pulse Check

No Man's Land: Why Cheap Stocks Can Still Be Hard Trades

Feb 6, 2026

•

11 min read

No Man's Land: Why Cheap Stocks Can Still Be Hard Trades

Jason Segal

The Pulse Check

Feb 5, 2026

•

9 min read

How medtech survives the SaaSpocolypes

Jason Segal

The Pulse Check

How the analysts separate signal from noise

Feb 4, 2026

•

13 min read

How the analysts separate signal from noise

Jason Segal

Starpharma (ASX:SPL)

The Platform Was the Prize: Starpharma’s 25-Year Pivot

Feb 3, 2026

•

12 min read

The Platform Was the Prize: Starpharma’s 25-Year Pivot

Jason Segal

The Pulse Check

What Happens After the Gold Rush? From Miners to Molecules

Feb 2, 2026

•

10 min read

What Happens After the Gold Rush? From Miners to Molecules

The Pulse Check

Is the RAT Back? The Return of Rapid Point-of-Care Diagnostics

Jan 30, 2026

•

12 min read

Is the RAT Back? The Return of Rapid Point-of-Care Diagnostics

The Pulse Check

My playbook for "confession season", also known as quarterly season

Jan 29, 2026

•

9 min read

My playbook for "confession season", also known as quarterly season

The Pulse Check

Jan 28, 2026

•

12 min read

Hunting for the Next 4DX

Noxopharm (ASX: NOX)

The Hard Pivot: What happens after a biotech reboots?

Jan 27, 2026

•

11 min read

The Hard Pivot: What happens after a biotech reboots?

The Pulse Check

The $2m Oversight: Don't forget to Exercise

Jan 23, 2026

•

5 min read

The $2m Oversight: Don't forget to Exercise

The Pulse Check

Big Volume, Boring News: Why Stocks Move on “Nothing”

Jan 22, 2026

•

9 min read

Big Volume, Boring News: Why Stocks Move on “Nothing”

The Pulse Check

Explained: Why Options Magnify Risk and Reward

Jan 21, 2026

•

12 min read

Explained: Why Options Magnify Risk and Reward

The Pulse Check

Whale Watching: What is driving the share price?

Jan 20, 2026

•

10 min read

Whale Watching: What is driving the share price?

The Pulse Check

On Edge: The Moment That Makes, or Breaks, a Biotech

Jan 19, 2026

•

13 min read

On Edge: The Moment That Makes, or Breaks, a Biotech

The Pulse Check

The Cannabis Merger Trade: Liquidity First, Value Later

Jan 16, 2026

•

11 min read

The Cannabis Merger Trade: Liquidity First, Value Later

Jason Segal

The Pulse Check

The moment that Chinese biotechs went from 'too hard' to 'too hard to ignore'

Jan 15, 2026

•

11 min read

The moment that Chinese biotechs went from 'too hard' to 'too hard to ignore'

Jason Segal

The Pulse Check

Jan 14, 2026

•

7 min read

The Art of the Capital Raise

Jason Segal

The Pulse Check

The Three-Day Market Update

The Price of Buying Time: The Adherium (ASX: ADR) Story

The Path to Blue-Chip: The Clarity Pharmaceuticals (ASX: CU6) Story

Why do stocks fall on good news

The Greatest Wealth Creator in Australian Biotech: The CSL Story

Why I'm not catching the CSL falling knife

A 20-Year Overnight Success: The Memphasys (ASX: MEM) Story.

Why fundamental analysis doesn't work for Biotech Stocks

No Man's Land: Why Cheap Stocks Can Still Be Hard Trades

How medtech survives the SaaSpocolypes

How the analysts separate signal from noise

The Platform Was the Prize: Starpharma’s 25-Year Pivot

What Happens After the Gold Rush? From Miners to Molecules

Is the RAT Back? The Return of Rapid Point-of-Care Diagnostics

My playbook for "confession season", also known as quarterly season

Hunting for the Next 4DX

The Hard Pivot: What happens after a biotech reboots?

The $2m Oversight: Don't forget to Exercise

Big Volume, Boring News: Why Stocks Move on “Nothing”

Explained: Why Options Magnify Risk and Reward

Whale Watching: What is driving the share price?

On Edge: The Moment That Makes, or Breaks, a Biotech

The Cannabis Merger Trade: Liquidity First, Value Later

The moment that Chinese biotechs went from 'too hard' to 'too hard to ignore'

The Art of the Capital Raise

The Armchair Analyst